Developer docs
API playgroundTry for free, no card

Search company profiles

Vaxdyn

Full company profile

uuid0002t53

Namestring
Vaxdyn
Legal namestring
Vaxdyn S.L.
Websiteurl
vaxdyn.com
Company typeenum
Private
Founded yearint
2011
Descriptiontext

Vaxdyn S.L. is a clinical-stage Spanish biotechnology company founded in 2011 as a spin-off from the Institute of Biomedicine of Seville, developing multi-valent vaccines to prevent infections caused by antibiotic-resistant bacteria. The company's lead candidate, KapaVax (VXD005), is an inactivated LPS-null (endotoxin-free) whole-cell Acinetobacter baumannii vaccine engineered to display conserved antigens from Pseudomonas aeruginosa and Klebsiella pneumoniae on its cell surface, targeting three of the WHO's most urgent antibiotic-resistant pathogens with a single immunogen. The platform, protected by international patent WO 2015/169809 granted in Europe, the USA, Japan, China, India and Mexico, has been expanded into a broader pipeline including AcinetoVax (monovalent A. baumannii), K-Vax, P-Vax, EcoVax (ExPEC), and AppeVax (veterinary), the last enabling a One-Health approach across human and livestock applications.

Vaxdyn is pre-revenue and not yet commercial, with all vaccine candidates in pre-clinical development and first-in-human proof-of-principle expected in 2025. The company is funded almost entirely by non-dilutive grants — up to US$7.3 million from CARB-X, €1.4 million from Next Generation EU via the Spanish State Research Agency, €397K from EUROSTARS/CDTI — supplemented by a €700K seed round in 2021 from Bionova Capital, Arquimea Group, and the Botín Foundation's Mind the Gap program. Operations are run from a small team of 11-50 employees in Dos Hermanas (Seville), Spain, executing development through an international consortium including Laboratorios Reig Jofre (manufacturing), LEITAT (process development), CSIC, CNM-ISCIII, and the University of Córdoba, with the University of Latvia added as a partner for clinical epidemiology planning.

Target end-markets once commercial include patients with chronic lung disease (COPD, cystic fibrosis, primary ciliary dyskinesia), immunocompromised populations (cancer, transplant, dialysis patients), neonates in low-to-middle-income settings, women with recurrent UTIs, hospital and nursing-home populations, and the porcine livestock industry — addressing a global AMR burden estimated at 700,000 annual deaths and a projected 10 million deaths per year by 2050. Vaxdyn currently positions itself through conference participation (World Vaccine Congress Europe), digital channels, and Spanish media, with no established sales infrastructure or pricing as commercial distribution remains several years away.

Short descriptiontext

Vaxdyn is a Spanish clinical-stage biotech developing multi-valent vaccines against WHO priority antibiotic-resistant bacteria, using a proprietary LPS-null whole-cell Acinetobacter baumannii platform led by KapaVax. It is pre-revenue, targeting vulnerable patient populations including COPD, immunocompromised, and neonatal patients.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSevilla, Spain
HQ citystring
Sevilla
HQ countrystring
Spain
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
vaccine development, antimicrobial resistance, multi-valent vaccines, whole-cell vaccines, biopharmaceutical research
Industry3 codes
PRIMARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAEAA
Prophylactic Human Vaccines (routine, pediatric, adult)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAMAKAB
Livestock Vaccines (Cattle, Swine, Sheep & Goats)
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceutical Vaccines
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Vaccine Development and Commercialization
TypeHardware Sales
Description

Vaxdyn is a clinical-stage biotech company developing vaccines against antibiotic-resistant bacteria. Revenue will be generated through vaccine product sales following regulatory approval. The company has not yet reached commercial stage as its vaccine candidates are in pre-clinical development.

vaxdyn.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Vaxdyn develops multi-valent inactivated whole-cell vaccines against antibiotic-resistant bacteria using a proprietary LPS-null (endotoxin-free) Acinetobacter baumannii platform that displays conserved outer-membrane antigens from multiple pathogens on the cell surface. The company's lead candidate KapaVax targets three of the WHO's top urgent-threat superbugs (A. baumannii, K. pneumoniae, P. aeruginosa), with pipeline extensions for additional human and veterinary pathogens.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 50% mortality rate reduction potential for patients with multi-drug resistant infections
+2 more records
Product overview1 text field

Vaxdyn is a vaccine development company offering a platform of inactivated LPS-null (endotoxin-free) whole-cell vaccines based on a proprietary Acinetobacter baumannii strain. The platform has evolved from the monovalent AcinetoVax into a technological infrastructure capable of delivering multi-valent vaccine candidates. The core products include AcinetoVax (monovalent A. baumannii vaccine), KapaVax (trivalent vaccine targeting A. baumannii, K. pneumoniae, and P. aeruginosa), and pipeline candidates K-Vax, P-Vax, EcoVax, and AppeVax, which extend the platform to additional pathogens for human and veterinary applications.

Product and service6 records
1AcinetoVax (VXD001)
CategoryCore vaccine product
Description

Inactivated LPS-null (endotoxin-free) whole-cell Acinetobacter baumannii vaccine for raising active immunity against antibiotic-resistant A. baumannii infections. Foundation candidate of Vaxdyn's platform technology.

2KapaVax (VXD005)
CategoryCore vaccine product
Description

Inactivated LPS-null (endotoxin-free) whole-cell Acinetobacter baumannii vaccine displaying at the cell surface multiple conserved antigens from Pseudomonas aeruginosa and Klebsiella pneumoniae. Trivalent vaccine targeting three of the WHO's most urgent antibiotic-resistant bacteria with a single immunogen.

3K-Vax
CategoryPipeline vaccine candidate
Description

Inactivated LPS-null whole-cell A. baumannii vaccine displaying multiple conserved antigens from Klebsiella pneumoniae on the cell surface, designed to raise immunity against 100% of circulating strains of K. pneumoniae and A. baumannii.

4P-Vax
CategoryPipeline vaccine candidate
Description

Inactivated LPS-null whole-cell A. baumannii vaccine displaying multiple conserved antigens from Pseudomonas aeruginosa on the cell surface, designed to raise immunity against 100% of circulating strains of P. aeruginosa and A. baumannii.

5EcoVax
CategoryPipeline vaccine candidate
Description

Inactivated LPS-null whole-cell A. baumannii vaccine displaying multiple conserved antigens from Extraintestinal Pathogenic Escherichia coli (ExPEC) on the cell surface, designed to prevent ExPEC and A. baumannii infections in at-risk community populations.

6AppeVax
CategoryVeterinary vaccine candidate
Description

Inactivated LPS-null whole-cell A. baumannii vaccine displaying multiple conserved antigens from Actinobacillus pleuropneumoniae on the cell surface, designed for prevention of porcine pleuropneumonia in the veterinary industry to reduce antibiotic use in livestock.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Barcelona-based international pharmaceutical manufacturer partnering with Vaxdyn in the AMReady consortium for vaccine development and manufacturing. Part of consortium led by Vaxdyn for developing vaccines against AMR pathogens.

2National Center of Microbiology (CNM) of ISCIII
Strategic tierCoreTypeStrategic or Co-development Partner
Description

National reference laboratory for infectious diseases control in Spain. Key research partner in vaccine development working on immunology and infectious disease aspects of Vaxdyn's vaccine candidates.

vaxdyn.com
3LEITAT Technology Center
Strategic tierCoreTypeTechnology or Integration
Description

Technology center in Barcelona providing technical expertise for vaccine development and manufacturing process development for Vaxdyn's vaccine candidates.

vaxdyn.com
4CSIC - Institute of Parasitology and Biomedicine López Neyra
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Spanish National Research Council institute in Granada contributing immunology expertise to Vaxdyn's vaccine development programs including AMReady consortium.

vaxdyn.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Faculty of Veterinary Sciences partnering with Vaxdyn for vaccine development including testing in porcine models for applications in veterinary industry and One-Health approach.

Strategic tierSecondaryTypeStrategic or Co-development Partner
Description

Partner in MultiVAX EUROSTARS project for clinical and commercial vaccination strategy against K. pneumoniae and A. baumannii. Includes Paul Stradins University Hospital in Riga for epidemiology assessment.

Strategic tierMinorTypeOthers
Description

Spanish Industry Association for biotech companies; Vaxdyn is a member for industry networking and advocacy.

Strategic tierMinorTypeOthers
Description

Biotech companies from Europe innovating in Anti-Microbial Resistance research; Vaxdyn is a member for collaboration and advocacy.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Swiss clinical-stage biotech developing vaccines against bacterial pathogens including AMR targets. Most directly comparable peer given similar AMR vaccine focus, European base, and pre-clinical-to-clinical stage profile.

TypeDirect peer
Description

Vaccine developer using a novel multiple antigen-presenting system (MAPS) platform for bacterial vaccines; acquired by GSK in 2022 for up to $3.3B. Closely comparable vaccine technology platform approach targeting AMR pathogens.

TypeDirect peer
Description

US-based biotech developing vaccines and immunotherapies against Staphylococcus aureus and other AMR pathogens. Comparable as a focused AMR vaccine developer with similar pipeline approach.

TypeDirect peer
Description

UK-based AMR-focused biotech developing novel therapeutics and vaccines against drug-resistant infections. Similar European footprint, AMR focus, and pre-clinical/early-clinical profile.

TypeEmerging player
Description

Dutch vaccine development and contract manufacturing organization developing vaccines against infectious diseases including AMR targets. Comparable as a European vaccine developer with overlapping technology and disease focus.

6Valneva
TypeBroad incumbent
Description

European specialty vaccine company with approved vaccines (chikungunya, Japanese encephalitis, TBE) and pipeline including AMR-relevant programs. Comparable as a publicly-traded European vaccine company operating at larger scale in same space.

TypeBroad incumbent
Description

German mRNA platform leader with publicly disclosed AMR vaccine programs. Potentially the most disruptive competitor as mRNA technology could address Vaxdyn's targets with much larger R&D and manufacturing resources.

TypeBroad incumbent
Description

US mRNA platform leader exploring bacterial vaccine applications including AMR pathogens. Comparable as a major vaccine platform player whose resources could enable competitive AMR vaccine development at scale.

TypeEmerging player
Description

French biotech developing novel antibacterial molecules against AMR pathogens. Adjacent AMR-focused biotech with similar European base and development stage, though addressing treatment rather than prevention.

TypeEmerging player
Description

Clinical-stage vaccine developer focused on norovirus with VLP-based platform technology. Comparable as a small-cap pre-commercial vaccine platform developer facing similar capital and clinical execution challenges.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Vaxdyn

Biopharmaceutical Vaccinesvaxdyn.com

Vaxdyn is a Spanish clinical-stage biotech developing multi-valent vaccines against WHO priority antibiotic-resistant bacteria, using a proprietary LPS-null whole-cell Acinetobacter baumannii platform led by KapaVax. It is pre-revenue, targeting vulnerable patient populations including COPD, immunocompromised, and neonatal patients.

What Vaxdyn does

Vaxdyn S.L. is a clinical-stage Spanish biotechnology company founded in 2011 as a spin-off from the Institute of Biomedicine of Seville, developing multi-valent vaccines to prevent infections caused by antibiotic-resistant bacteria. The company's lead candidate, KapaVax (VXD005), is an inactivated LPS-null (endotoxin-free) whole-cell Acinetobacter baumannii vaccine engineered to display conserved antigens from Pseudomonas aeruginosa and Klebsiella pneumoniae on its cell surface, targeting three of the WHO's most urgent antibiotic-resistant pathogens with a single immunogen. The platform, protected by international patent WO 2015/169809 granted in Europe, the USA, Japan, China, India and Mexico, has been expanded into a broader pipeline including AcinetoVax (monovalent A. baumannii), K-Vax, P-Vax, EcoVax (ExPEC), and AppeVax (veterinary), the last enabling a One-Health approach across human and livestock applications.

Vaxdyn is pre-revenue and not yet commercial, with all vaccine candidates in pre-clinical development and first-in-human proof-of-principle expected in 2025. The company is funded almost entirely by non-dilutive grants — up to US$7.3 million from CARB-X, €1.4 million from Next Generation EU via the Spanish State Research Agency, €397K from EUROSTARS/CDTI — supplemented by a €700K seed round in 2021 from Bionova Capital, Arquimea Group, and the Botín Foundation's Mind the Gap program. Operations are run from a small team of 11-50 employees in Dos Hermanas (Seville), Spain, executing development through an international consortium including Laboratorios Reig Jofre (manufacturing), LEITAT (process development), CSIC, CNM-ISCIII, and the University of Córdoba, with the University of Latvia added as a partner for clinical epidemiology planning.

Target end-markets once commercial include patients with chronic lung disease (COPD, cystic fibrosis, primary ciliary dyskinesia), immunocompromised populations (cancer, transplant, dialysis patients), neonates in low-to-middle-income settings, women with recurrent UTIs, hospital and nursing-home populations, and the porcine livestock industry — addressing a global AMR burden estimated at 700,000 annual deaths and a projected 10 million deaths per year by 2050. Vaxdyn currently positions itself through conference participation (World Vaccine Congress Europe), digital channels, and Spanish media, with no established sales infrastructure or pricing as commercial distribution remains several years away.

Vaxdyn firmographics

Firmographics
Name
Vaxdyn
Legal name
Vaxdyn S.L.
Website
https://vaxdyn.com
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
11–50 employees
Short description
Vaxdyn is a Spanish clinical-stage biotech developing multi-valent vaccines against WHO priority antibiotic-resistant bacteria, using a proprietary LPS-null whole-cell Acinetobacter baumannii platform led by KapaVax. It is pre-revenue, targeting vulnerable patient populations including COPD, immunocompromised, and neonatal patients.
Ownership category
akta.pro rank

Vaxdyn industry classification

Industry
Product category
Biopharmaceutical Vaccines
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAEAA
Prophylactic Human Vaccines (routine, pediatric, adult)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAMAKAB
Livestock Vaccines (Cattle, Swine, Sheep & Goats)

Keywords

  • Vaccine development
  • Antimicrobial resistance
  • Multi-valent vaccines
  • Whole-cell vaccines
  • Biopharmaceutical research

Where Vaxdyn is headquartered

Location

Headquarters

HQ city
Sevilla
HQ country
Spain
HQ region
Europe

Offices1 record

Markets served

Vaxdyn business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Vaccine Development and Commercialization: Vaxdyn is a clinical-stage biotech company developing vaccines against antibiotic-resistant bacteria. Revenue will be generated through vaccine product sales following regulatory approval. The company has not yet reached commercial stage as its vaccine candidates are in pre-clinical development.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Vaxdyn product offering

Product offering

Core offering

Vaxdyn develops multi-valent inactivated whole-cell vaccines against antibiotic-resistant bacteria using a proprietary LPS-null (endotoxin-free) Acinetobacter baumannii platform that displays conserved outer-membrane antigens from multiple pathogens on the cell surface. The company's lead candidate KapaVax targets three of the WHO's top urgent-threat superbugs (A. baumannii, K. pneumoniae, P. aeruginosa), with pipeline extensions for additional human and veterinary pathogens.

Product overview

Vaxdyn is a vaccine development company offering a platform of inactivated LPS-null (endotoxin-free) whole-cell vaccines based on a proprietary Acinetobacter baumannii strain. The platform has evolved from the monovalent AcinetoVax into a technological infrastructure capable of delivering multi-valent vaccine candidates. The core products include AcinetoVax (monovalent A. baumannii vaccine), KapaVax (trivalent vaccine targeting A. baumannii, K. pneumoniae, and P. aeruginosa), and pipeline candidates K-Vax, P-Vax, EcoVax, and AppeVax, which extend the platform to additional pathogens for human and veterinary applications.

Differentiator

Problem solved

Functional benefit

Products and services

  • AcinetoVax (VXD001) Inactivated LPS-null (endotoxin-free) whole-cell Acinetobacter baumannii vaccine for raising active immunity against antibiotic-resistant A. baumannii infections. Foundation candidate of Vaxdyn's platform technology.
  • KapaVax (VXD005) Inactivated LPS-null (endotoxin-free) whole-cell Acinetobacter baumannii vaccine displaying at the cell surface multiple conserved antigens from Pseudomonas aeruginosa and Klebsiella pneumoniae. Trivalent vaccine targeting three of the WHO's most urgent antibiotic-resistant bacteria with a single immunogen.
  • K-Vax Inactivated LPS-null whole-cell A. baumannii vaccine displaying multiple conserved antigens from Klebsiella pneumoniae on the cell surface, designed to raise immunity against 100% of circulating strains of K. pneumoniae and A. baumannii.
  • P-Vax Inactivated LPS-null whole-cell A. baumannii vaccine displaying multiple conserved antigens from Pseudomonas aeruginosa on the cell surface, designed to raise immunity against 100% of circulating strains of P. aeruginosa and A. baumannii.
  • EcoVax Inactivated LPS-null whole-cell A. baumannii vaccine displaying multiple conserved antigens from Extraintestinal Pathogenic Escherichia coli (ExPEC) on the cell surface, designed to prevent ExPEC and A. baumannii infections in at-risk community populations.
  • AppeVax Inactivated LPS-null whole-cell A. baumannii vaccine displaying multiple conserved antigens from Actinobacillus pleuropneumoniae on the cell surface, designed for prevention of porcine pleuropneumonia in the veterinary industry to reduce antibiotic use in livestock.

Quantifiable outcome

  • 50% mortality rate reduction potential for patients with multi-drug resistant infections
  • +2 more outcomes

Companies that use Vaxdyn

Customer profile

Segments6 records

Ideal customer profiles5 records

Vaxdyn technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Vaxdyn partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core, secondary and minor.

  • Laboratorios Reig JofrecoreStrategic or Co-development PartnerBarcelona-based international pharmaceutical manufacturer partnering with Vaxdyn in the AMReady consortium for vaccine development and manufacturing. Part of consortium led by Vaxdyn for developing vaccines against AMR pathogens.
  • National Center of Microbiology (CNM) of ISCIIIcoreStrategic or Co-development PartnerNational reference laboratory for infectious diseases control in Spain. Key research partner in vaccine development working on immunology and infectious disease aspects of Vaxdyn's vaccine candidates.
  • LEITAT Technology CentercoreTechnology or IntegrationTechnology center in Barcelona providing technical expertise for vaccine development and manufacturing process development for Vaxdyn's vaccine candidates.
  • CSIC - Institute of Parasitology and Biomedicine López NeyracoreStrategic or Co-development PartnerSpanish National Research Council institute in Granada contributing immunology expertise to Vaxdyn's vaccine development programs including AMReady consortium.
  • University of CórdobacoreStrategic or Co-development PartnerFaculty of Veterinary Sciences partnering with Vaxdyn for vaccine development including testing in porcine models for applications in veterinary industry and One-Health approach.
  • University of LatviasecondaryStrategic or Co-development PartnerPartner in MultiVAX EUROSTARS project for clinical and commercial vaccination strategy against K. pneumoniae and A. baumannii. Includes Paul Stradins University Hospital in Riga for epidemiology assessment.
  • ASEBIOminorOthersSpanish Industry Association for biotech companies; Vaxdyn is a member for industry networking and advocacy.
  • BEAM AllianceminorOthersBiotech companies from Europe innovating in Anti-Microbial Resistance research; Vaxdyn is a member for collaboration and advocacy.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Vaxdyn competitors and assessment

Company assessment

Direct peers

  • LimmaTech Biologics: Swiss clinical-stage biotech developing vaccines against bacterial pathogens including AMR targets. Most directly comparable peer given similar AMR vaccine focus, European base, and pre-clinical-to-clinical stage profile.
  • Affinivax: Vaccine developer using a novel multiple antigen-presenting system (MAPS) platform for bacterial vaccines; acquired by GSK in 2022 for up to $3.3B. Closely comparable vaccine technology platform approach targeting AMR pathogens.
  • Integrated Biotherapeutics: US-based biotech developing vaccines and immunotherapies against Staphylococcus aureus and other AMR pathogens. Comparable as a focused AMR vaccine developer with similar pipeline approach.
  • Centauri Therapeutics: UK-based AMR-focused biotech developing novel therapeutics and vaccines against drug-resistant infections. Similar European footprint, AMR focus, and pre-clinical/early-clinical profile.

Emerging players

  • Intravacc: Dutch vaccine development and contract manufacturing organization developing vaccines against infectious diseases including AMR targets. Comparable as a European vaccine developer with overlapping technology and disease focus.
  • Nosopharm: French biotech developing novel antibacterial molecules against AMR pathogens. Adjacent AMR-focused biotech with similar European base and development stage, though addressing treatment rather than prevention.
  • HilleVax: Clinical-stage vaccine developer focused on norovirus with VLP-based platform technology. Comparable as a small-cap pre-commercial vaccine platform developer facing similar capital and clinical execution challenges.

Broad incumbents

  • Valneva: European specialty vaccine company with approved vaccines (chikungunya, Japanese encephalitis, TBE) and pipeline including AMR-relevant programs. Comparable as a publicly-traded European vaccine company operating at larger scale in same space.
  • BioNTech: German mRNA platform leader with publicly disclosed AMR vaccine programs. Potentially the most disruptive competitor as mRNA technology could address Vaxdyn's targets with much larger R&D and manufacturing resources.
  • Moderna: US mRNA platform leader exploring bacterial vaccine applications including AMR pathogens. Comparable as a major vaccine platform player whose resources could enable competitive AMR vaccine development at scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Vaxdyn social profiles

Digital presence

Vaxdyn financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Vaxdyn leadership team

Management profile

Number of profiles

Profiles14 records

Vaxdyn funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Vaxdyn M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vaxdyn

What does Vaxdyn do?

Vaxdyn develops multi-valent inactivated whole-cell vaccines against antibiotic-resistant bacteria using a proprietary LPS-null (endotoxin-free) Acinetobacter baumannii platform that displays conserved outer-membrane antigens from multiple pathogens on the cell surface. The company's lead candidate KapaVax targets three of the WHO's top urgent-threat superbugs (A. baumannii, K. pneumoniae, P. aeruginosa), with pipeline extensions for additional human and veterinary pathogens.

Is Vaxdyn a public or private company?

Vaxdyn is a private company. It is classified as venture growth investor backed and is currently operating.

When was Vaxdyn founded?

Vaxdyn was founded in 2011. It employs 11 to 50 people.

Where is Vaxdyn based?

Vaxdyn is headquartered in Sevilla, Spain, in the Europe region.

How does Vaxdyn make money?

One revenue line is on record: vaccine Development and Commercialization.

Who are Vaxdyn's main competitors?

Direct peers on record are LimmaTech Biologics, Affinivax, Integrated Biotherapeutics and Centauri Therapeutics. Emerging players are Intravacc, Nosopharm and HilleVax. Broad incumbents are Valneva, BioNTech and Moderna.

Does Vaxdyn have an API?

No public API is recorded for Vaxdyn.

What industry is Vaxdyn in?

Vaxdyn's product category is Biopharmaceutical Vaccines. Its primary akta.pro industry code is HLAAAEAD, Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA), with a secondary code of HLAAAEAA, Prophylactic Human Vaccines (routine, pediatric, adult). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
WebcapitalriesgoBiovance Capital, Arcano Partners y el Fondo EIC invierten €11M en Vaxdyn para impulsar el desarrollo clínicoVaxdyn raised €11M in a Series A round led by Biovance Capital, with participation from the EIC and Arcano's Impacto Andalucía fund. The funding will finance the Phase 1 clinical trial of its K-VAX vaccine against antibiotic-resistant bacteria. The company also received non-dilutive support from EIC Accelerator and CARB-X.Empresas de Capital Riesgo en EspaBiovance Capital, Arcano Partners and the EIC Fund invest €11 million in Vaxdyn to advance clinical developmentBiovance Capital, the EIC Fund, and Arcano Partners invested €11 million in Spanish biotech Vaxdyn in a Series A round. The funding will enable a Phase 1 clinical trial for K-VAX, a vaccine candidate against Klebsiella pneumoniae and Acinetobacter baumannii. The company also received non-dilutive support from EIC Accelerator and CARB-X.El ReferenteVaxdyn recibe una inversión de 11 M€Vaxdyn raised €11 million in a Series A round led by Biovance Capital, with participation from the EIC and Arcano Partners. The funds will support a Phase 1 clinical trial for its K-VAX vaccine against antibiotic-resistant bacteria. The company also received non-dilutive funding from EIC Accelerator and CARB-X.El ReferenteVaxdyn recibe una inversión de 11 M€Vaxdyn raised €11 million in a Series A round led by Biovance Capital, with participation from the EIC and Arcano Partners. The funds will support a Phase 1 clinical trial for its K-VAX vaccine candidate against antibiotic-resistant bacteria. The company also received non-dilutive funding from EIC Accelerator and CARB-X.El ReferenteVaxdyn recibe una inversión de 11 M€Vaxdyn raised €11 million in a Series A round led by Biovance Capital, with participation from the EIC and Arcano Partners. The funds will support a Phase 1 clinical trial for its K-VAX vaccine candidate against antibiotic-resistant bacteria. The company also received non-dilutive funding from EIC Accelerator and CARB-X.El ReferenteVaxdyn recibe una inversión de 11 M€Vaxdyn raised €11 million in a Series A round led by Biovance Capital, with participation from the EIC and Arcano Partners. The funds will support a Phase 1 clinical trial for its K-VAX vaccine candidate against antibiotic-resistant bacteria. The company also received non-dilutive funding from EIC Accelerator and CARB-X.European BiotechnologyVaxdyn raises €11M Series A to test AMR vaccineVaxdyn raised €11M in a Series A to enter a first-in-human Phase 1 trial for K-VAX, its vaccine against Klebsiella pneumoniae and Acinetobacter baumannii. The round was led by Biovance Capital with €4M, joined by the EIC Fund and Impacto Andalusia. The funding will support clinical validation of its antimicrobial resistance vaccine platform.VaxdynBiovance Capital, Arcano Partners and the EIC Fund invest €11 million in Vaxdyn to advance clinical developmentBiovance Capital, the EIC Fund, and Arcano Partners' Impacto Andalucía invested €11 million in Vaxdyn's Series A round. The funding will fund the first-in-human Phase 1 trial of Vaxdyn's lead vaccine candidate K-VAX against antibiotic-resistant bacteria. The company also received non-dilutive support from EIC Accelerator and CARB-X.BioWorldK-Vax shows broad protection across circulating K. pneumoniae strainsResearchers from Vaxdyn SL and collaborators presented efficacy data for K-Vax, an inactivated, LPS-null whole-cell A. baumannii-based vaccine engineered to display conserved K. pneumoniae outer-membrane proteins. The vaccine shows broad protection across circulating K. pneumoniae strains, addressing both K. pneumoniae and A. baumannii, major contributors to the global antimicrobial resistance crisis.AsebioVaxdyn awarded €14.5 Million from the EIC Accelerator to Fund the Clinical Phase of Its Vaccine PlatformVaxdyn has been awarded €14.5 million from the European Commission's EIC Accelerator program to fund the clinical validation of its vaccine platform targeting antibiotic-resistant bacteria. The funding consists of a €2.5 million grant for Phase 1 trials and €12 million in equity investment for Phase 2 efficacy testing against Klebsiella pneumoniae.